Economic evaluation of a bivalent respiratory syncytial virus prefusion F vaccine for older adults in Sweden: cost-effectiveness and budget impact

Introducing RSVpreF vaccination for older adults in Sweden has the potential to reduce RSV-related hospitalizations, deaths, and healthcare costs. Findings support the implementation of RSV vaccination to older adults and at-risk individuals as a cost-effective and budget-saving strategy in the short term.

Authors

Máté Szilcz (ORCID: https://orcid.org/0000-0002-9291-0559)
Samira Toghanian
Andreas Palmborg (ORCID: https://orcid.org/0000-0002-4833-112X)
Ann-Charlotte Fridh
Parissa Naghipour

Institutions

Pfizer (United States) (US)
Karolinska Institutet (SE)
Pfizer (Sweden) (SE)
Vitrolife (Sweden) (SE)
Viti (United States) (US)

Publication Details

Journal: Journal of Medical Economics
Published: 2025-10-25
DOI: https://doi.org/10.1080/13696998.2025.2580785
Citations: 1
Primary Topic: Respiratory viral infections research
Type: article
Field-Weighted Citation Impact: 1.35

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Economic evaluation of a bivalent respiratory syncytial virus prefusion F vaccine for older adults in Sweden: cost-effectiveness and budget impact

Máté Szilcz, Samira Toghanian, Andreas Palmborg, Ann-Charlotte Fridh et al.

Oct 25, 2025

1 citations

Journal of Medical Economics

Respiratory viral infections research

1.35

article

Economic evaluation of a bivalent respiratory syncytial virus prefusion F vaccine for older adults in Sweden: cost-effectiveness and budget impact

Máté Szilcz, Samira Toghanian, Andreas Palmborg, Ann-Charlotte Fridh, Parissa Naghipour

October 25, 2025article en

1 citations

Abstract

Introducing RSVpreF vaccination for older adults in Sweden has the potential to reduce RSV-related hospitalizations, deaths, and healthcare costs. Findings support the implementation of RSV vaccination to older adults and at-risk individuals as a cost-effective and budget-saving strategy in the short term.

Journal of Medical EconomicsVol. 28(1)

Pfizer (United States) (US), Karolinska Institutet (SE), Pfizer (Sweden) (SE), Vitrolife (Sweden) (SE), Viti (United States) (US)

Openalex Percentile: Top 14%

Respiratory viral infections research

1.35

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Economic evaluation of a bivalent respiratory syncytial virus prefusion F vaccine for older adults in Sweden: cost-effectiveness and budget impact — Máté Szilcz, Samira Toghanian, et al. · Journal of Medical Economics (2025) | TGRS Research Map | TGRS